Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Heparase (Endo Glucoronidase or Heparase 1 or HPSE or EC 3.2.1.166) - Overview
Heparase (Endo Glucoronidase or Heparase 1 or HPSE or EC 3.2.1.166) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Heparase (Endo Glucoronidase or Heparase 1 or HPSE or EC 3.2.1.166) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Heparase (Endo Glucoronidase or Heparase 1 or HPSE or EC 3.2.1.166) - Companies Involved in Therapeutics Development
Beta Therapeutics Pty Ltd
CarboMimetics
HepaRx Ltd
Leadiant Biosciences Inc
Momenta Pharmaceuticals Inc
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Zucero Therapeutics Ltd
Heparase (Endo Glucoronidase or Heparase 1 or HPSE or EC 3.2.1.166) - Drug Profiles
Antibodies to Inhibit Heparase for Alopecia, Colitis, Diabetic Nephropathy, Bone Marrow Transplant Rejection and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-2180 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-30119 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-1710 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
necuparanib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pixatimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharides to Inhibit Heparase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
roneparstat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Heparase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Heparase for Inflammatory Diseases and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Heparase for Type 1 and Type 2 Diabetes and Age Related Macular Degeneration - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit HPSE and VEGF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heparase (Endo Glucoronidase or Heparase 1 or HPSE or EC 3.2.1.166) - Dormant Products
Heparase (Endo Glucoronidase or Heparase 1 or HPSE or EC 3.2.1.166) - Discontinued Products
Heparase (Endo Glucoronidase or Heparase 1 or HPSE or EC 3.2.1.166) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Products under Development by Companies, H2 2020 (Contd..3), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Actavalon Inc, H2 2020
Pipeline by Active Biotech AB, H2 2020
Pipeline by Ampio Pharmaceuticals Inc, H2 2020
Pipeline by AnTolRx Inc, H2 2020
Pipeline by Bayer AG, H2 2020
Pipeline by Dermavant Sciences Inc, H2 2020
Pipeline by Hercules Pharmaceuticals BV, H2 2020
Pipeline by Hutchison MediPharma Ltd, H2 2020
Pipeline by Ikena Oncology Inc, H2 2020
Pipeline by JAGUAHR Therapeutics Pte Ltd, H2 2020
Pipeline by Magenta Therapeutics Inc, H2 2020
Pipeline by Pfizer Inc, H2 2020
Pipeline by Phenex Pharmaceuticals AG, H2 2020
Pipeline by Shenogen Pharma?Group Ltd, H2 2020
Pipeline by Sol-Gel Technologies Ltd, H2 2020
Pipeline by Welichem Biotech Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020